Detailed Information on Publication Record
2023
Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol
HOLCOVÁ POLANSKÁ, Hana, Kateřina PETRLÁKOVÁ, Barbora PAPOUSKOVA, Michal HENDRYCH, Amir SAMADIAN et. al.Basic information
Original name
Safety assessment and redox status in rats after chronic exposure to cannabidiol and cannabigerol
Authors
HOLCOVÁ POLANSKÁ, Hana (203 Czech Republic, belonging to the institution), Kateřina PETRLÁKOVÁ (203 Czech Republic, belonging to the institution), Barbora PAPOUSKOVA (203 Czech Republic), Michal HENDRYCH (203 Czech Republic, belonging to the institution), Amir SAMADIAN (364 Islamic Republic of Iran, belonging to the institution), Jan STORCH (203 Czech Republic), Petr BABULA (203 Czech Republic, belonging to the institution), Michal MASAŘÍK (203 Czech Republic, belonging to the institution) and Jan VACEK (203 Czech Republic, guarantor)
Edition
Toxicology, CLARE, ELSEVIER IRELAND LTD, 2023, 0300-483X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30108 Toxicology
Country of publisher
Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.500 in 2022
RIV identification code
RIV/00216224:14110/23:00130557
Organization unit
Faculty of Medicine
UT WoS
000962570900001
Keywords in English
Phytocannabinoid; in vivo experiment; Antioxidant; CBD protective properties; CBG toxicity
Tags
International impact, Reviewed
Změněno: 27/4/2023 10:13, Mgr. Tereza Miškechová
Abstract
V originále
Cannabidiol (CBD) and cannabigerol (CBG) are the two main non-psychotropic phytocannabinoids with high application potential in drug development. Both substances are redox-active and are intensively investigated for their cytoprotective and antioxidant action in vitro. In this study, we focused on an in vivo safety evaluation and the effect of CBD and CBG on the redox status in rats in a 90-d experiment. The substances were administered orogastrically in a dose of 0.66 mg synthetic CBD or 0.66 mg/1.33 mg CBG/kg/day. CBD produced no changes in the red or white blood count or biochemical blood parameters in comparison to the control. No deviations in the morphology or histology of the gastrointestinal tract and liver were observed. After 90 d of CBD exposure, a significant improvement in redox status was found in the blood plasma and liver. The concentration of malondialdehyde and carbonylated proteins was reduced compared to the control. In contrast to CBD, total oxidative stress was significantly increased and this was accompanied by an elevated level of malondialdehyde and carbonylated proteins in CBG-treated animals. Hepatotoxic (regressive changes) manifestations, disruption in white cell count, and alterations in the ALT activity, level of creatinine and ionized calcium were also found in CBG-treated animals. Based on liquid chromatography-mass spectrometry analysis, CBD/CBG accumulated in rat tissues (in the liver, brain, muscle, heart, kidney and skin) at a low ng level per gram. Both CBD and CBG molecular structures include a resorcinol moiety. In CBG, there is an extra dimethyloctadienyl structural pattern, which is most likely responsible for the disruption to the redox status and hepatic environment. The results are valuable to further investigation of the effects of CBD on redox status and should contribute towards opening up critical discussion on the applicability of other non-psychotropic cannabinoids.